The role of autophagy inhibition in the enhanced cytotoxicity of temozolomide on melanoma cell lines

Cover Page

Cite item

Full Text

Abstract

Background. Despite advantages in treatment of metastatic melanoma it remains resistant to current therapy. Recent evidence indicates that tumor cells could overcome death through autophagy, a process that degrades cellular proteins and organelles to maintain cellular biosynthesis during nutrient deprivation or lack of energy. Objective: to investigate the involvement of autophagy inhibitors chloroquine (CQ) and LY-294.002 (LY) in temozolomide (TMZ) cytotoxicity in human melanoma cell lines.

Materials and methods. The study was performed on patient-derived melanoma cell lines Mel Z, Mel IL and Mel MTP. The antiproliferative activity of combined TMZ and autophagy inhibitors treatment was determined by MTT assay and colony-forming assay. Cell cycle analysis, apoptosis activation and expression analysis of key autophagy markers under combined treatment was evaluated.

Results. CQ and LY enhanced the cytotoxicity of TMZ and reduced colony formation in 3 melanoma cell lines, moreover both inhibitors increased cell population in G0 / G1 phase of cell cycle in Mel Z, Mel IL cell lines, but not in Mel MTP. CQ and LY synergistically activated apoptosis in all cell lines. The matrix RNA expression analysis of key autophagy genes showed autophagy involvement in enhanced cytotoxicity.

Conclusions. Thus, autophagy inhibition on different stages of this process could overcome resistance to TMZ and be applicable as potent target in metastatic melanoma treatment.

About the authors

O. O. Ryabaya

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia.

Author for correspondence.
Email: oxa2601@yandex.ru
1 Ostrovityanovа St., Moscow 117997. Russian Federation

A. N. Inshakov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia.

Email: fake@neicon.ru
24 Kashirskoye Shosse, Moscow 115478. Russian Federation

A. A. Malysheva

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia.

Email: fake@neicon.ru
24 Kashirskoye Shosse, Moscow 115478. Russian Federation

I. S. Abramov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; V.A. Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences.

Email: fake@neicon.ru
32 Vavilova St., Moscow 119991. Russian Federation

N. V. Sholina

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia.

Email: fake@neicon.ru
24 Kashirskoye Shosse, Moscow 115478. Russian Federation

D. A. Khochenkov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia.

Email: fake@neicon.ru
24 Kashirskoye Shosse, Moscow 115478. Russian Federation

E. V. Stepanova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia.

Email: fake@neicon.ru
24 Kashirskoye Shosse, Moscow 115478. Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c)



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.